Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.
Aggarwal NR, Beaty LE, Bennett TD, Fish LE, Jacobs JR, Mayer DA, Molina KC, Peers JL, Richardson DB, Russell S, Varela A, Webb BJ, Wynia MK, Xiao M, Carlson NE, Ginde AA. Aggarwal NR, et al. Among authors: molina kc. Lancet Reg Health Am. 2024 Feb 9;31:100693. doi: 10.1016/j.lana.2024.100693. eCollection 2024 Mar. Lancet Reg Health Am. 2024. PMID: 38500962 Free PMC article.
Early Experience With Eravacycline for Complicated Infections.
Alosaimy S, Molina KC, Claeys KC, Andrade J, Truong J, King MA, Pullinger BM, Huang G, Morrisette T, Lagnf AM, Davis SL, Rybak MJ. Alosaimy S, et al. Among authors: molina kc. Open Forum Infect Dis. 2020 Mar 2;7(5):ofaa071. doi: 10.1093/ofid/ofaa071. eCollection 2020 May. Open Forum Infect Dis. 2020. PMID: 32411809 Free PMC article.
Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Aggarwal NR, et al. Among authors: molina kc. Int J Infect Dis. 2023 Mar;128:310-317. doi: 10.1016/j.ijid.2022.10.002. Epub 2022 Oct 10. Int J Infect Dis. 2023. PMID: 36229005 Free PMC article.
Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients.
Douin DJ, Wogu AF, Beaty LE, Carlson NE, Bennett TD, Aggarwal NR, Mayer DA, Ong TC, Russell S, Steele J, Peers JL, Molina KC, Wynia MK, Ginde AA. Douin DJ, et al. Among authors: molina kc. BMC Infect Dis. 2022 Nov 7;22(1):818. doi: 10.1186/s12879-022-07819-z. BMC Infect Dis. 2022. PMID: 36344927 Free PMC article.
Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Aggarwal NR, et al. Among authors: molina kc. Lancet Infect Dis. 2023 Jun;23(6):696-705. doi: 10.1016/S1473-3099(23)00011-7. Epub 2023 Feb 10. Lancet Infect Dis. 2023. PMID: 36780912 Free PMC article.
Real-world use of nirmatrelvir-ritonavir: who benefits?
Molina KC, Ginde AA. Molina KC, et al. Lancet Infect Dis. 2023 Jul;23(7):765-767. doi: 10.1016/S1473-3099(23)00180-9. Epub 2023 Mar 15. Lancet Infect Dis. 2023. PMID: 36933566 Free PMC article. No abstract available.
Effectiveness of subcutaneous monoclonal antibody treatment in emergency department outpatients with COVID-19.
Wendel SK, Wogu AF, Carlson NE, Beaty L, Bennett TD, Bookman K, Mayer DA, Michael SM, Molina KC, Peers JL, Russell S, Zane RD, Ginde AA. Wendel SK, et al. Among authors: molina kc. J Am Coll Emerg Physicians Open. 2024 Feb 21;5(1):e13116. doi: 10.1002/emp2.13116. eCollection 2024 Feb. J Am Coll Emerg Physicians Open. 2024. PMID: 38384380 Free PMC article.
46 results